Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Study sponsor: BioCryst Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-04-10Actual
Enrollment · participants121Actual
Source updated2023-06-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.